74654-05-0

Usage

Uses

Used in Pharmaceutical Industry:
Methyl-PEG3-MS is used as a molecular linker for improving the solubility and bioavailability of drugs. The hydrophilic PEG spacer increases the drug's solubility in aqueous environments, while the mesyl group facilitates nucleophilic substitution reactions, allowing for the attachment of various drug molecules.
Used in Chemical Synthesis:
In the field of chemical synthesis, Methyl-PEG3-MS serves as a versatile building block for the creation of complex molecules. The mesyl group's reactivity as a leaving group enables the formation of new chemical bonds through nucleophilic substitution reactions, making it a valuable component in the synthesis of various compounds.
Used in Bioconjugation:
Methyl-PEG3-MS is used as a bioconjugation agent to attach biologically active molecules, such as peptides, proteins, or nucleic acids, to other molecules or surfaces. The PEG spacer provides a hydrophilic environment that can reduce aggregation and non-specific interactions, while the mesyl group allows for efficient coupling through nucleophilic substitution.
Used in Drug Delivery Systems:
In drug delivery systems, Methyl-PEG3-MS can be utilized as a component of targeted drug carriers. The PEG spacer can improve the solubility and circulation time of the drug in the body, while the mesyl group can be used to attach targeting ligands or other functional groups to enhance the specificity and efficacy of the drug delivery system.
Overall, Methyl-PEG3-MS is a multifunctional molecule with a wide range of applications in various industries, including pharmaceuticals, chemical synthesis, bioconjugation, and drug delivery systems. Its unique structure, combining a hydrophilic PEG spacer with a reactive mesyl group, makes it a valuable tool for improving solubility, bioavailability, and reactivity in a variety of contexts.

Upstream product

• 112-35-6 triethylene glucol monomethyl ether 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 130955-44-1 C₃₆H₄₂O₈ 
• 74654-06-1 2-(2-(2-methoxyethoxy)ethoxy)ethyl azide 
• 339354-86-8 methyl 3-{2-[2-(2-methoxyethoxy)ethoxy]ethoxy}-2-methylbenzoate 
• 339354-90-4 3-({2-[2-(2-methoxyethoxy)ethoxy]ethyl}sulfanyl)-2-methylbenzyl alcohol 
• 153364-63-7 4-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)benzaldehyde 
• 23783-42-8 tetraethylene glycol monomethyl ether 
• 868159-50-6 3-(2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy)-benzaldehyde 
• 852628-92-3 methyl 3,4,5-tris(2-(2-(2-methoxyethoxy)ethoxy)-ethoxy)benzoate 
• 552846-10-3 4-METHOXY-2-{2-[2-(2-METHOXYETHOXY)ETHOXY]ETHOXY}-5-THIOPHEN-2-YL-benzaldehyde 
• 873848-07-8 3,5-bis-(2-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-benzoic acid 
• 873848-25-0 carbonic acid 3,5-bis-(2-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-benzyl ester 4-nitro-phenyl ester 
• 873848-09-0 3,5-Bis-(2-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-benzoic acid (2S,3R,4R,5S,6R)-2-allyloxy-5-hydroxy-6-hydroxymethyl-3-(2,2,2-trichloro-ethoxycarbonylamino)-tetrahydro-pyran-4-yl ester 
• 873848-13-6 N-[4-((2S,3R,4S,5R,6R)-4-Benzyloxy-5-hydroxy-6-hydroxymethyl-2-methoxy-tetrahydro-pyran-3-yloxymethyl)-phenyl]-3,5-bis-(2-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-benzamide 
• 873848-08-9 3,5-Bis-(2-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-benzoic acid (2R,4aR,6S,7R,8R,8aS)-6-allyloxy-2-phenyl-7-(2,2,2-trichloro-ethoxycarbonylamino)-hexahydro-pyrano[3,2-d][1,3]dioxin-8-yl ester 

Relevant academic research and scientific papers

NEUROACTIVE STEROIDS AND COMPOSITIONS AND METHODS THEREOF

The invention provides novel neuroactive steroids and pharmaceutical compositions thereof, as well as methods of their preparation and use, in therapy of various diseases and conditions, for example, various neurological or brain diseases.

Naloxegol Oxalate and Solid Dispersion thereof

The present invention relates to solid dispersion of Naloxegol oxalate. Further, the present invention relates to an improved process for Naloxegol oxalate and intermediates thereof.

MULTI-ELECTRON REDOX-ACTIVE ORGANIC MOLECULES FOR HIGH-ENERGY-DENSITY NONAQUEOUS REDOX FLOW BATTERIES

The invention relates to 1,4-diaminoanthraquinones and an electrolyte, and their use in batteries.

triAZOLOtriAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS

The present invention provides triazolotriazine derivatives of formula (1) as A2A receptor antagonists. Compounds of formula (1) and pharmaceutical compositions including the compounds can be used for the treatment of disorders related to A2A receptor hyperfunctioning, such as certain types cancers. Compounds of formula (1) and methods of preparing the compounds are disclosed in the invention.

DENDRITIC POLYETHYLENE GLYCOL DERIVATIVE, AND PREPARATION METHOD AND APPLICATION THEREOF

The disclosure discloses a dendritic polyethylene glycol derivative and a preparation method and an application thereof. The dendritic polyethylene glycol derivative has a structure of formula (I), has multiple end functional groups, has a stronger water solubility in comparison with linear-chain polyethylene glycol, and can solve a problem of insufficient water solubility due to the increase of load when modifying an insoluble drug by the polyethylene glycol. The preparation method of the dendritic polyethylene glycol derivative provided by the disclosure has mild reaction conditions, is green and environmentally friendly, is low in cost, and is easy to implement industrialization.

NOVEL TRITERPENE DERIVATIVES AS HIV INHIBITORS

The present invention relates to novel triterpene derivatives of formula (I); and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and ring are as defined herein. The invention also relates to novel triterpene derivatives, related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases.

Anion Recognition in Water by Charge-Neutral Halogen and Chalcogen Bonding Foldamer Receptors

A novel strategy for the recognition of anions in water using charge-neutral σ-hole halogen and chalcogen bonding acyclic hosts is demonstrated for the first time. Exploiting the intrinsic hydrophobicity of halogen and chalcogen bond donor atoms integrated into a foldamer structural molecular framework containing hydrophilic functionalities, a series of water-soluble receptors was constructed for an anion recognition investigation. Isothermal titration calorimetry (ITC) binding studies with a range of anions revealed the receptors to display very strong and selective binding of large, weakly hydrated anions such as I- and ReO4-. This is achieved through the formation of 2:1 host-guest stoichiometric complex assemblies, resulting in an encapsulated anion stabilized by cooperative, multidentate, convergent σ-hole donors, as shown by molecular dynamics simulations carried out in water. Importantly, the combination of multiple σ-hole-anion interactions and hydrophobic collapse results in I- affinities in water that exceed all known σ-hole receptors, including cationic systems (β2 up to 1.68 × 1011 M-2). Furthermore, the anion binding affinities and selectivity trends of the first example of an all-chalcogen bonding anion receptor in pure water are compared with halogen bonding and hydrogen bonding receptor analogues. These results further advance and establish halogen and chalcogen bond donor functions as new tools for overcoming the challenging goal of anion recognition in pure water.

A halogen-bonding foldamer molecular film for selective reagentless anion sensing in water

We describe self-assembled monolayers of novel halogen-bonding and hydrogen-bonding foldamer receptors capable of selectively recruiting perrhenate, iodide and thiocyanate in water. Unprecedented anion sensing via impedance-derived capacitance spectroscopy enables subsequent sensitive and selective anion detection without the need for a redox probe. Importantly, the sensing of any anion should be possible using this novel electrochemical approach.

AN IMPROVED PROCESS FOR THE PREPARATION OF (5Α,6Α)-17-ALLYL-6-(2,5,8,11,14,17,20- HEPTAOXADOCOSAN-22-YLOXY)-4,5-EPOXYMORPHINAN-3,14-DIOL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS

The present invention relates to an improved process for the preparation of (5α, 6α)-17-allyl-6-(2, 5, 8, 11, 14, 17, 20- heptaoxadocosan-22-yloxy)-4, 5-epoxymorphinan-3, 14-diol which is represented by the following structural formula-1 or its pharmaceut

NALOXEGOL OXALATE AND SOLID DISPERSION THEREOF

The present invention relates to solid dispersion of Naloxegol oxalate. Further, the present invention relates to an improved process for Naloxegol oxalate and intermediates thereof.